We describe an ELISA for serum lgG antibodies against malondialdetiyde-modifledlow-density lipoprotein(mLDL). Optimal antigen concentration,serum dilution,and dilution of enzyme-conjugated second antibody were 25 mg/L, 1:250, and 1:5000, respectively, when 5 gIL human serum albuminwas used for blocking.When data were expressed as mLDL/LDL (the ratio of lgG binding to mLDL vs LDL), within-run and between-run CVs were 7.0% and 8.9%, respectively.Antibody concentrationsexpressed as mLDL/ LOL or as mLDL-LDL (the difference between lgG binding to mWL and to LDL) were higher in women with systemic lupus erythematosus (n = 20) than in controls (n = 20) (P <0.001). With bovine serum albumin or Superblock blockingbuffers,only the mLDL-LOL data were significant. Thus, the choice of blockingagent and the method of data expression should be carefully considered when assaying lgG antibodies against mLDL. 
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With bovine serum albumin or Superblock blockingbuffers,only the mLDL-LOL data were significant. Thus, the choice of blockingagent and the method of data expression should be carefully considered when assaying lgG antibodies against mLDL. 
Sera
The assay was developed with sera received for mirelated clinical testing in our laboratory; these sera were stored in aliquots for 6 months to 2 years at -20#{176}C before use. Sera from subjects with and without SLE were identified from samples that entered our labora- The concentration ofantibody against mLDL, estimated as mLDL/LDL,was assayed by ELISA(with BSA) in three sera (all stored frozen at -20'C) over 8 weeks after WL and mLDL preparation.Each point represents the mean ± SD for the three sara, each assayed in duplicate. Comparative data for the three blocking buffers are presented in Table 2 ; 18 sera randomly selected from samples entering our laboratory for clinical testing were assayed. These experiments were performed with optima! experimental conditions for each blocking buffer, as given in Table 1 In theory, the ratio should not change, because the increases in LDL and mLDL concentration were the same; 
Serum dilution.
To determine the optimal serum dilution for the assay of serum antibodies against mLDL, we examined mLDLJLDL over a range of serum dilutions; antigen concentration was 25 mg/L and the enzyme-conjugated second antibody was diluted 1:5000.
mLDLILDL increased
with increasing serum dilution, to a maximum at 1:100 (n = 6); however, the ratio between the high value and the low value was greatest at 1:250 (Fig. 4B) Maximum values for mLDIILDL were reached at a dilution of 1:5000 (n = 7); there was no apparent trend in the high value/low value ratio with enzyme-conjugated second antibody dilution (Fig. 4C) .
Precision
To the best of our knowledge, the question of assay precision (CV) has not been addressed in previous reports. We therefore examined both within-run and between-run precision (HSA blocking buffer, optimized experimental conditions) with six serum samples with a range of antibody concentrations.
All sera were stored in aliquots at -20#{176}C before assay. As illustrated in Table 3 , the best precision was obtained when the data were expressed as mLDL/LDL rather than as inLDL-LDL. Normalization of the absorbance data significantly improved between-run precision when data were expressed as mLDL-LDL, although the value remained high (CV 30.5%) compared with between-run precision for mLDLILDL (CV 8.9%).
IgG Antibodies Against mLDL in SLE Patients and Controls
To examine the effect of different assay methodology and methods of data expression on study outcome, we IgOautoantibodles againstmLDL were assayed by EUSA (with HSA blocking buffer). Sara were assayed in duplicate 11 limes (within-run study) or8 times (between-run study). Data are expressed as mean ± SD for 6 sara. reported that concentrations of antibody to oxidized LDL were higher in SLE patients than in controls (data expressed as mLDL-LDL; HSA for blocking).
Our results (Table 4) Superblock and 10 g/L BSA are less effective than 5 g/L HSA in reducing nonspecific binding. Thus, in a study where there are differences in nonspecific binding between patients and controls (as is very likely with SLE), differences in the amounts of IgG antibody against mLDL between groups may not be adequately assessed when the data are expressed as mLDLILDL, unless HSA is used for blocking.
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are not affected by differences in nonspecific binding. 
